*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.
Abbott Laboratories is poised to showcase its resilience once again as it prepares to release its third-quarter earnings on October 15, 2025. With a market cap of over $232 billion, the company's strategic focus on its core medical device business continues to pay dividends, as evidenced by its robust second-quarter performance, where it exceeded Wall Street expectations with an EPS of $1.26. Analysts are now forecasting an EPS of $1.30 for the upcoming quarter, with a whisper number slightly higher at $1.35, signaling optimism for another potential beat. Revenue is projected to reach $11.40 billion, building on the company's consistent sales growth, which saw a 7.4% increase in Q2. Despite some market concerns about muted earnings growth, Abbott's strong base business and expanding medtech pipeline, particularly in continuous glucose monitoring, are expected to drive sustained performance. Investors will be keenly watching for any updates on Abbott's full-year guidance, especially after the company raised its profit forecast earlier this year, underscoring its confidence in navigating current market challenges.
Abbott Laboratories is an American multinational medical devices and health care company with headquarters in Abbott Park, Illinois, United States. The company was founded by Chicago physician Wallace Calvin Abbott in 1888 to formulate known drugs; today, it sells medical devices, diagnostics, branded generic medicines and nutritional products. It split off its research-based pharmaceuticals business into AbbVie in 2013.
Website: https://www.abbott.com
Average Sentiment Score:
Overall Sentiment: